CD274 and hepatocellular carcinoma: To explore this therapeutic approach, a randomized phase I/II study (NCT02519348) [78] was conducted, investigating the safety and efficacy of tremelimumab (a CTLA-4 inhibitor) in combination with durvalumab (a PD-L1 inhibitor) in unresectable HCC patients.